Actionable news
0
All posts from Actionable news
Actionable news in RDHL: Redhill Biopharma Ltd.,

Redhill Biopharma To Host Third Quarter 2015 Financial Results Conference Call On November 9, 2015 EXHIBIT 99.1

The following excerpt is from the company's SEC filing.

RedHill Biopharma to Host Third Quarter 2015 Financial Results Conference Call on November 9, 2015

TEL-AVIV, Israel, Oct. 29, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced that it will report financial results for the third quarter of 2015 on Monday, November 9, 2015.

The Company will also host a conference call on Monday, Novemb er 9, 2015, at 9:00 am EST to review the financial results and business highlights.

To participate in the conference call, please dial the following numbers five to ten minutes prior to the start of the call:

United States: +1-877-280-1254; International: +1-212-444-0412; and Israel: +972-3-721-9510. The access code for the call is 7362435.

The conference call will be broadcasted live and available for replay on the Company's website,

http://ir.redhillbio.com/events.cfm

, for 30 days. Please access the Company's website at least 15 minutes ahead of the conference to register, download, and install any necessary audio software.

About RedHill Biopharma Ltd.:

RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) is an emerging Israeli biopharmaceutical company primarily focused on the development of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of inflammatory and gastrointestinal diseases, including cancer. RedHill's current pipeline of proprietary products includes: (i)

RHB-105

an oral combination therapy for the treatment of

Helicobacter pylori

infection with successful top-line results from a first Phase III study; (ii)

RHB-104

an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study; (iii)

BEKINDA

(RHB-102)

a once-daily oral pill formulation of ondansetron with an ongoing Phase III study in the U.S. for acute gastroenteritis and gastritis and a European marketing application for chemotherapy...


More